743 related articles for article (PubMed ID: 34305920)
21. LLT1-CD161 Interaction in Cancer: Promises and Challenges.
Braud VM; Meghraoui-Kheddar A; Elaldi R; Petti L; Germain C; Anjuère F
Front Immunol; 2022; 13():847576. PubMed ID: 35185935
[TBL] [Abstract][Full Text] [Related]
22. Calreticulin, a potential coregulator of immune checkpoints and biomarker associated with tumor microenvironment and clinical prognostic significance in breast invasive carcinoma.
Lin J; Chen Y; Zhang Z; Qi F; Zhang M
Environ Toxicol; 2024 May; 39(5):2717-2731. PubMed ID: 38247288
[TBL] [Abstract][Full Text] [Related]
23. Comprehensive analyses of tumor immunity: implications for cancer immunotherapy.
Li B; Severson E; Pignon JC; Zhao H; Li T; Novak J; Jiang P; Shen H; Aster JC; Rodig S; Signoretti S; Liu JS; Liu XS
Genome Biol; 2016 Aug; 17(1):174. PubMed ID: 27549193
[TBL] [Abstract][Full Text] [Related]
24. Colorectal Cancer-Associated Immune Exhaustion Involves T and B Lymphocytes and Conventional NK Cells and Correlates With a Shorter Overall Survival.
Sorrentino C; D'Antonio L; Fieni C; Ciummo SL; Di Carlo E
Front Immunol; 2021; 12():778329. PubMed ID: 34975867
[TBL] [Abstract][Full Text] [Related]
25. Immunogenomic pathways associated with cytotoxic lymphocyte infiltration and survival in colorectal cancer.
Shen Y; Guan Y; Hummel JJ; Shyu CR; Mitchem JB
BMC Cancer; 2020 Feb; 20(1):124. PubMed ID: 32059711
[TBL] [Abstract][Full Text] [Related]
26. The Expression Pattern and Clinical Significance of the Immune Checkpoint Regulator VISTA in Human Breast Cancer.
Xie X; Zhang J; Shi Z; Liu W; Hu X; Qie C; Chen W; Wang Y; Wang L; Jiang J; Liu J
Front Immunol; 2020; 11():563044. PubMed ID: 33250890
[TBL] [Abstract][Full Text] [Related]
27. TRPV4 is a Prognostic Biomarker that Correlates with the Immunosuppressive Microenvironment and Chemoresistance of Anti-Cancer Drugs.
Wang K; Feng X; Zheng L; Chai Z; Yu J; You X; Li X; Cheng X
Front Mol Biosci; 2021; 8():690500. PubMed ID: 34262942
[No Abstract] [Full Text] [Related]
28. Identification of SLC12A8 as a valuable prognostic biomarker and immunotherapeutic target by comprehensive pan-cancer analysis.
Yu D; Ma H; Li D; Tang H; Li W; Li M
Gene; 2024 Apr; 903():148211. PubMed ID: 38280496
[TBL] [Abstract][Full Text] [Related]
29. POC1A, prognostic biomarker of immunosuppressive microenvironment in cancer.
Zhao Q; Gao S; Chen X; Zhu X
Aging (Albany NY); 2022 Jun; 14(12):5195-5210. PubMed ID: 35748773
[TBL] [Abstract][Full Text] [Related]
30. High expression of immune checkpoints is associated with the TIL load, mutation rate and patient survival in colorectal cancer.
Kitsou M; Ayiomamitis GD; Zaravinos A
Int J Oncol; 2020 Jul; 57(1):237-248. PubMed ID: 32468013
[TBL] [Abstract][Full Text] [Related]
31. FOXD1 is a prognostic biomarker and correlated with macrophages infiltration in head and neck squamous cell carcinoma.
Liang H; Zhang C; Li C; Li C; Wang Y; Lin H
Biosci Rep; 2021 Jul; 41(7):. PubMed ID: 34028536
[TBL] [Abstract][Full Text] [Related]
32. Prevalence of PRKDC mutations and association with response to immune checkpoint inhibitors in solid tumors.
Chen Y; Li Y; Guan Y; Huang Y; Lin J; Chen L; Li J; Chen G; Pan LK; Xia X; Xu N; Chang L; Guo Z; Pan J; Yi X; Chen C
Mol Oncol; 2020 Sep; 14(9):2096-2110. PubMed ID: 32502294
[TBL] [Abstract][Full Text] [Related]
33. Analysis of the role of Frizzled 2 in different cancer types.
Zhou M; Sun X; Zhu Y
FEBS Open Bio; 2021 Apr; 11(4):1195-1208. PubMed ID: 33565732
[TBL] [Abstract][Full Text] [Related]
34. The expression profiling and clinical significance of a chronic pain-related gene IL1R1.
Zhou L; Wu C; Li R; Wang L; Han D
Cell Mol Biol (Noisy-le-grand); 2023 May; 69(5):163-167. PubMed ID: 37571886
[TBL] [Abstract][Full Text] [Related]
35. [Immune Microenvironment Comparation Study between EGFR Mutant and EGFR Wild Type Lung Adenocarcinoma Patients Based on TCGA Database].
Zhu G; Li Y; Shi R; Xu S; Zhang Z; Cao P; Chen C; Liu H; Chen J
Zhongguo Fei Ai Za Zhi; 2021 Apr; 24(4):236-244. PubMed ID: 33910272
[TBL] [Abstract][Full Text] [Related]
36. Discordance of immunotherapy response predictive biomarkers between primary lesions and paired metastases in tumours: A systematic review and meta-analysis.
Zou Y; Hu X; Zheng S; Yang A; Li X; Tang H; Kong Y; Xie X
EBioMedicine; 2021 Jan; 63():103137. PubMed ID: 33310681
[TBL] [Abstract][Full Text] [Related]
37. A comprehensive analysis of immune infiltration in the tumor microenvironment of osteosarcoma.
Yang H; Zhao L; Zhang Y; Li FF
Cancer Med; 2021 Aug; 10(16):5696-5711. PubMed ID: 34258887
[TBL] [Abstract][Full Text] [Related]
38. Cancer Immunotherapies: From Efficacy to Resistance Mechanisms - Not Only Checkpoint Matters.
Wang S; Xie K; Liu T
Front Immunol; 2021; 12():690112. PubMed ID: 34367148
[TBL] [Abstract][Full Text] [Related]
39. Pan-Cancer Analysis of Immune Cell Infiltration Identifies a Prognostic Immune-Cell Characteristic Score (ICCS) in Lung Adenocarcinoma.
Zuo S; Wei M; Wang S; Dong J; Wei J
Front Immunol; 2020; 11():1218. PubMed ID: 32714316
[No Abstract] [Full Text] [Related]
40. MIR155HG is a prognostic biomarker and associated with immune infiltration and immune checkpoint molecules expression in multiple cancers.
Peng L; Chen Z; Chen Y; Wang X; Tang N
Cancer Med; 2019 Dec; 8(17):7161-7173. PubMed ID: 31568700
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
